Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Uzi Sofer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 121
- Beta
- 1.22
- Country
- IL
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 5.59
Financials
Net Income
$-45.81MEBITDA
$-13.78MFree Cash Flow
$0.00EPS (diluted)
$-0.50Shares Outstanding (diluted)
90.95M+34.5%Operating Expenses
$13.78MCash & Debt
$100.64MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-42.63M | $-0.53 |
| 2024 | $0.00 | $-31.75M | $-0.45 |
| 2023 | $0.00 | $-29.16M | $-0.42 |
| 2022 | $0.00 | $-33.76M | $-0.53 |
| 2021 | $0.00 | $-27.27M | $-0.40 |
| 2020 | $0.00 | $-8.88M | $-0.13 |
| 2019 | $0.00 | $-8.46M | $-0.13 |
Valuation
DRTShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-3.23%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·10d ago·Neutral
Alpha Tau to Participate in October Investor Conferences JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that company management will participate in the following investor conferences in October 2026.
View source ↗ - Newsseekingalpha.com·34d ago·Neutral
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More Oramed Pharmaceuticals Inc. maintains a Hold rating as it pivots from drug development to strategic investments, with significant progress in asset growth and portfolio diversification. ORMP's investments in Lifeward and Scilex have yielded strong returns, including a near tripling of its $38.2M Alpha Tau Medical stake and robust loan recovery from Scilex. Alpha Tau Medical's Alpha DaRT product, with approvals in J
View source ↗ - Newsseekingalpha.com·41d ago·Negative
Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough Alpha Tau is positioned for a transformative inflection point with potentially groundbreaking GBM data expected before year-end and pancreatic shortly after. Two out of first three GBM patients achieved a complete response (CR), essentially unheard of in GBM. Alpha Tau is still severely underknown to investors, adding to its re-rating potential.
View source ↗ - Newsglobenewswire.com·43d ago·Neutral
Alpha Tau to Participate in September Investor Conferences JERUSALEM, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd.
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
…hat also includes the ACAPELLA trial in France and a study at the University of Verona - JERUSALEM, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the completion of patient enrollment in its IMPACT study (Intratumoral Pancreatic Alpha Combination Trial) - a multicenter pilot study evaluating intratumoral Alpha DaRT in combination with first-line chemotherapy …
View source ↗
Earnings
Thu, Nov 19(in 5 weeks)
Consensus estimate $-0.14 per share
Typical surprise -8.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.50 vs $-0.14miss
- Mon, May 18$-0.26 vs $-0.13miss
- Mon, Mar 9$-0.14 vs $-0.13miss
- Thu, Nov 20$-0.14 vs $-0.12miss
- Mon, Aug 11$-0.13 vs $-0.12miss
- Mon, May 19$-0.12 vs $-0.14beat
Estimates and results for DRTS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DRTS officers and directors.
- Bought
- —
- Sold
- $1.6m
0 trades
12 trades
- Levy Raphisold
- Levy Raphisold
- Levy Raphisold
- Levy Raphisold
- Levy Raphisold
- Levy Raphisold
- Levy Raphisold
- Levy Raphisold
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DRTS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.